The mechanism of action of sunitinib is also linked to the process of healing and against the formation of new blood vessels [33], while denosumab attaches to the RANKL cytokine and despite its antiresorptive effect, can produce osteonecrosis. This evidence concerns the gene TNFSF11 and osteonecrosis.